SIGNIFICANCE: Anthracyclines (doxorubicin, daunorubicin, or epirubicin) rank among the most effective anticancer drugs, but their clinical usefulness is hampered by the risk of cardiotoxicity. The most feared are the chronic forms of cardiotoxicity, characterized by irreversible cardiac damage and congestive heart failure. Although the pathogenesis of anthracycline cardiotoxicity seems to be complex, the pivotal role has been traditionally attributed to the iron-mediated formation of reactive oxygen species (ROS). In clinics, the bisdioxopiperazine agent dexrazoxane (ICRF-187) reduces the risk of anthracycline cardiotoxicity without a significant effect on response to chemotherapy. The prevailing concept describes dexrazoxane as a prodrug undergoing bioactivation to an iron-chelating agent ADR-925, which may inhibit anthracycline-induced ROS formation and oxidative damage to cardiomyocytes. RECENT ADVANCES: A considerable body of evidence points to mitochondria as the key targets for anthracycline cardiotoxicity, and therefore it could be also crucial for effective cardioprotection. Numerous antioxidants and several iron chelators have been tested in vitro and in vivo with variable outcomes. None of these compounds have matched or even surpassed the effectiveness of dexrazoxane in chronic anthracycline cardiotoxicity settings, despite being stronger chelators and/or antioxidants. CRITICAL ISSUES: The interpretation of many findings is complicated by the heterogeneity of experimental models and frequent employment of acute high-dose treatments with limited translatability to clinical practice. FUTURE DIRECTIONS: Dexrazoxane may be the key to the enigma of anthracycline cardiotoxicity, and therefore it warrants further investigation, including the search for alternative/complementary modes of cardioprotective action beyond simple iron chelation.

Department of Pharmacology Charles University Prague Hradec Králové Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc13031899

003      

CZ-PrNML

005      

20181207131404.0

007      

ta

008      

131002s2013 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1089/ars.2012.4795 $2 doi

035    __

$a (PubMed)22794198

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Štěrba, Martin $u Department of Pharmacology, Charles University in Prague, Hradec Králové, Czech Republic. sterbam@lfhk.cuni.cz $7 xx0076492

245    10

$a Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection / $c M. Stěrba, O. Popelová, A. Vávrová, E. Jirkovský, P. Kovaříková, V. Geršl, T. Simůnek,

520    9_

$a SIGNIFICANCE: Anthracyclines (doxorubicin, daunorubicin, or epirubicin) rank among the most effective anticancer drugs, but their clinical usefulness is hampered by the risk of cardiotoxicity. The most feared are the chronic forms of cardiotoxicity, characterized by irreversible cardiac damage and congestive heart failure. Although the pathogenesis of anthracycline cardiotoxicity seems to be complex, the pivotal role has been traditionally attributed to the iron-mediated formation of reactive oxygen species (ROS). In clinics, the bisdioxopiperazine agent dexrazoxane (ICRF-187) reduces the risk of anthracycline cardiotoxicity without a significant effect on response to chemotherapy. The prevailing concept describes dexrazoxane as a prodrug undergoing bioactivation to an iron-chelating agent ADR-925, which may inhibit anthracycline-induced ROS formation and oxidative damage to cardiomyocytes. RECENT ADVANCES: A considerable body of evidence points to mitochondria as the key targets for anthracycline cardiotoxicity, and therefore it could be also crucial for effective cardioprotection. Numerous antioxidants and several iron chelators have been tested in vitro and in vivo with variable outcomes. None of these compounds have matched or even surpassed the effectiveness of dexrazoxane in chronic anthracycline cardiotoxicity settings, despite being stronger chelators and/or antioxidants. CRITICAL ISSUES: The interpretation of many findings is complicated by the heterogeneity of experimental models and frequent employment of acute high-dose treatments with limited translatability to clinical practice. FUTURE DIRECTIONS: Dexrazoxane may be the key to the enigma of anthracycline cardiotoxicity, and therefore it warrants further investigation, including the search for alternative/complementary modes of cardioprotective action beyond simple iron chelation.

650    _2

$a antracykliny $x škodlivé účinky $x chemie $x farmakologie $7 D018943

650    _2

$a antitumorózní látky $x škodlivé účinky $x chemie $x farmakologie $7 D000970

650    _2

$a antioxidancia $x chemie $x farmakologie $7 D000975

650    _2

$a kardiotonika $x škodlivé účinky $x chemie $x farmakologie $7 D002316

650    _2

$a chelátory $x škodlivé účinky $x chemie $x farmakologie $7 D002614

650    _2

$a srdce $x účinky léků $7 D006321

650    _2

$a lidé $7 D006801

650    _2

$a kovy $x škodlivé účinky $7 D008670

650    _2

$a myokard $x metabolismus $7 D009206

650    _2

$a oxidace-redukce $7 D010084

650    12

$a oxidační stres $7 D018384

650    _2

$a razoxan $x škodlivé účinky $x chemie $x farmakologie $7 D011929

650    _2

$a reaktivní formy kyslíku $x metabolismus $7 D017382

650    12

$a signální transdukce $7 D015398

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

655    _2

$a přehledy $7 D016454

700    1_

$a Lenčová-Popelová, Olga $u - $7 _BN001885

700    1_

$a Vávrová, Anna $u - $7 _AN050099

700    1_

$a Jirkovský, Eduard $u - $7 uk20201094982

700    1_

$a Štěrbová-Kovaříková, Petra $u - $7 mzk2007411146

700    1_

$a Geršl, Vladimír, $u - $d 1946-2015 $7 nlk19990073168

700    1_

$a Šimůnek, Tomáš $u - $7 xx0019029

773    0_

$w MED00006026 $t Antioxidants & redox signaling $x 1557-7716 $g Roč. 18, č. 8 (2013), s. 899-929

856    41

$u https://pubmed.ncbi.nlm.nih.gov/22794198 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20131002 $b ABA008

991    __

$a 20181207131522 $b ABA008

999    __

$a ok $b bmc $g 995986 $s 830344

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2013 $b 18 $c 8 $d 899-929 $i 1557-7716 $m Antioxidants & redox signaling $n Antioxid. Redox Signal. $x MED00006026

GRA    __

$a NT13457 $p MZ0

LZP    __

$a Pubmed-20131002